By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Tim FerrissPsychedelics — Microdosing, Mind Enhancing Methods, and More | The Tim Ferriss Show (Podcast)
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
A panel on psychedelic therapy: risks, mechanisms, trials, and legalization
- The episode is a panel discussion on psychedelic science and policy recorded at the 2019 Milken Institute Global Conference, featuring researchers, an investor, and an author discussing both data and lived experience.
- Matthew Johnson describes clinical findings for high-dose psilocybin in cancer-related depression/anxiety and early results for smoking cessation, while emphasizing standardized safety guidelines and known risk categories.
- Ayelet Waldman explains what microdosing means in her usage and recounts a personal 30-day LSD microdosing experiment that she says substantially improved her depression and daily functioning.
- Robin Carhart-Harris outlines proposed mechanisms involving serotonin 2A receptors, increased complexity of brain activity, default mode network disruption, and the idea that psychedelics relax rigid beliefs to enable therapeutic change with support.
- The panel also addresses scheduling/legal pathways, business-model questions for treatments that may work in few sessions, and the shared view that supervised, context-rich delivery models are crucial for safety and efficacy.
IDEAS WORTH REMEMBERING
5 ideasThe modern research community is proactively standardizing safety practices and reassessing scheduling based on evidence.
He emphasized that “bad trips” and other downsides are real, and described published guidelines that institutional review boards and the FDA use to evaluate protocols; he also argued that if psilocybin is approved via Phase III trials, available data suggest Schedule IV is a better fit than Schedule I.
Some clinical trial results suggest durable mental-health benefits from one or a few guided high-dose sessions.
He described a Johns Hopkins study where a single high-dose psilocybin session produced large reductions in clinically severe depression and anxiety, with effects persisting at six months; he contrasted this with ketamine’s shorter-lived effects as he characterized them.
Early addiction research in psychedelics is being positioned as ‘transdiagnostic’—potentially applicable across multiple addictions.
He shared an open-label smoking-cessation pilot using psilocybin sessions, reporting high biologically verified abstinence rates at follow-ups and noting a randomized trial was underway; he framed psychedelics’ anti-addiction effects as potentially broad rather than substance-specific.
Microdosing, as described here, is presented as non-intoxicating yet potentially mood-altering for some individuals.
She defined microdosing as taking a sub-perceptual dose (no hallucinations) and described a 30-day personal experiment microdosing LSD every three days after other medications hadn’t worked well for her; she reported improved mood, appreciation of beauty, and productivity.
Mechanistic and experiential accounts are linked: brain-level effects and the nature of the experience both matter for outcomes.
He said psychedelics act primarily via serotonin 2A receptors and reported findings that psychedelics increase the richness/complexity of brain activity above normal waking levels; he added that the subjective quality of the acute experience predicts therapeutic outcomes.
WORDS WORTH SAVING
5 quotesWe can look at some of the efficacy data very quickly.
— Matthew Johnson
So microdosing is the practice of taking a sub-perceptual dose of a psychedelic drug.
— Ayelet Waldman
Over the course of the next period that I was taking LSD microdoses, it wasn't like every day was a really good day, but many days were really good days.
— Ayelet Waldman
And what psychedelics seem to do acutely during the experience itself is they seem to relax beliefs and open a window for change, for revision.
— Robin Carhart-Harris
It was The single most meaningful thing I've ever done and experienced in my whole life. Full stop.
— Christian Angermayer
SPEAKERS
Tim Ferriss
hostPodcaster and author, host of The Tim Ferriss Show.
Ayelet Waldman
guestAuthor and former lawyer/criminal law professor known for writing about microdosing in A Really Good Day.
Matthew Johnson
guestProfessor of Psychiatry and Behavioral Sciences at Johns Hopkins University researching psychedelics and addiction.
Robin Carhart-Harris
guestNeuroscientist researching psychedelic mechanisms such as the default mode network and therapeutic change.
Christian Angermayer
guestGerman entrepreneur and biotech investor associated with bringing psychedelics to regulated medical markets (e.g., ATAI Life Sciences).
High quality AI-generated summary created from speaker-labeled transcript.
